[1]Arroyo V, Terra C, Gines P.Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome[J].J Hepatol, 2007, 46 (5) :935-946.
|
[2]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56-62.
|
[3]Salern F, Gerbes A, Gines P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome with cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.
|
[4]Angemary B, Ceina M, Karnel F, et al.Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemie shunt[J].Gut, 2003, 56 (2) :879-885.
|
[5]García-Paqan JC, Caca K, Bureau C, et al.Early use of TIPS in Patients with cirrhosis and variceal bleeding[J].N Engl J Med, 2010, 362 (25) :2370-2379.
|
[6]Cardenas A, Gines P.Hepatorenal syndrome[J].Clin Liver Dis, 2006, 10 (2) :371-385.
|
[7]Wong F, Moore K, Dingemanse J, et al.Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type-2 hepatorenal syndrome[J].Hepatology, 2008, 47 (1) :160-168.
|
[8]Fernández J, Monteagudo J, Bargallo X, et al.A randomized unblended pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis[J].Hepatology, 2005, 42 (3) :627-634.
|
[9]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type1 hepatorenal syndrome[J].Gastroenterology, 2008, 134 (5) :1360-1368.
|
[10]Krag A, Bendtsen F, Henriksen JH, et al.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J].Gut, 2010, 59 (1) :105-110.
|
[11]Moore KP, Aithal GP.Guidelines on the management of ascites in cirrhosis[J].Gut, 2006, 55 (Suppl 6) :vi1-12.
|
[12]Rssle M, Gerbes AL.TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax:a critical update[J].Gut, 2010, 59 (7) :988-1000.
|
[1] | Qianmei CAO, Zhechuan MEI. Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(10): 2439-2443. doi: 10.3969/j.issn.1001-5256.2021.10.038 |
[2] | YAN YongFeng, JIANG Xin, ZHONG Rui, XU Huan, PENG Yan, TANG XiaoWei. Value of hyponatremia in predicting disease severity of patients with acute pancreatitis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2765-2770. doi: 10.3969/j.issn.1001-5256.2020.12.025 |
[3] | LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005 |
[4] | Wu Jian, Yin Fang, Luo GuanHong, Zhu ShaoHua, Li Hong, Zhang Jing, Zheng YangYang, Sun Han, Zhou XinMin. Association of hyponatremia with degree of liver injury and complications in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(2): 277-280. doi: 10.3969/j.issn.1001-5256.2017.02.014 |
[5] | Chen ChengLiang, Song Wei, Meng XiuNa, Tian Xing, Jiao Jian. Significance of serum ischemia-modified albumin level in evaluating liver function in patients with liver cirrhosis of various causes[J]. Journal of Clinical Hepatology, 2016, 32(8): 1534-1537. doi: 10.3969/j.issn.1001-5256.2016.08.020 |
[6] | You Jia, Jiang JiaJi. Mechanisms of hyponatremia in patients with decompensated liver cirrhosis treated with terlipressin and related treatment principles[J]. Journal of Clinical Hepatology, 2016, 32(11): 2191-2194. doi: 10.3969/j.issn.1001-5256.2016.11.043 |
[7] | Li Ying, Xu JiZhe, Liang LiNa, Liu LiNa. Relationship of hyponatremia with degree of liver injury and prognosis in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 499-502. doi: 10.3969/j.issn.1001-5256.2016.03.021 |
[8] | Chen Si, Sun ZhangYu, Zhang ZhiHao, Wang YingYing. Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(8): 782-784. doi: 10.3969/j.issn.1001-5256.2014.08.021 |
[9] | Zheng XiaoLi, Wang LiangZhi, He JianHua, Xiang XingChao, Zhou XiangYu. Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2013, 29(8): 627-630. doi: 10.3969/j.issn.1001-5256.2013.08.019 |
[10] | Gao BaoXiu, Nie Xin, Wu Bin, He Yong, Song HaoLan, Luo TongXing, Xu Jing, Li GuiXing. Implications of elevated levels of prostaglandin I2 and thromboxane A2 in type I hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2012, 28(11): 860-862. |
[11] | Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561. |
[12] | Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109. |
[13] | Hu YuLin, Quan XiangLan. Research state and prospect of hyponatremia in cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(3): 330-332. |
[14] | Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817. |
[15] | Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560. |
[16] | Zhan GuoQing, Tan HuaBing, Zhu Lin, Li RuGui, Du WeiXing, Zhang WeiWei. A retrospective analysis of 145 cases with decompensation cirrhosis hyponatremia[J]. Journal of Clinical Hepatology, 2010, 26(2): 194-195+198. |
[17] | Chen FuMing, Huang Qun, Ji RengBin, Li GuiXia. The significance of serum TNF-α determination in patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2007, 23(6): 436-438. |